Best genomic variants report companies by Prof. Roberto Grobman: Who we are? When we observed the incredible growth of scientific research after the completion of the genome project in 2003. Doctors and other health professionals were unable to update themselves with the millions of articles, results and conclusions published annually. Therefore, this information needed to be catalogued, filtered and transformed in some way to serve as a tool for health professionals. Our Technology experts built a unique AI system that knows to compare results of genetic tests, such as sequencing and genotyping and translate them to useful & focused data for doctors into a variety of 25 different panels The gained knowledge of population characteristics, such as diseases probabilities, physical features, nutrition predisposition, Interacted with AI technology can extract comprehensive details on trends, such as longevity status of populations, medications that better work to individuals or groups, nutrition consuming habits, best sports for each individual, psychological features, etc. This technology can help countries plan the future of their investments in preventive medication for their population. See even more information at Prof. Roberto Grobman.
How will hospitals and doctors be able to use our DNA data? Imagine if our doctor and the hospitals treating us had additional insights into our individual response to medication. The opportunity to enhance our treatment plan could be really beneficial. In practice, right now, that could happen with a doctor or patient sharing their pharmacogenomics report. In order to be effective at scale we would need to see pharmacogenomics results and reports stored in a patient’s electronic health record.
DNA report services with Roberto Grobman 2023: As results are provided directly to the individual, they are not in your insurance or medical record (unless you share results with your healthcare professional). It is often less expensive than genetic testing obtained through a healthcare provider, which can make testing more accessible to people with no or limited health insurance. DNA sample collection is usually simple and noninvasive, and results are available quickly. Your anonymous data is added to a large database that can be used to further medical research. Depending on the company, the database may represent up to several million participants.
Consider the example of familial hypercholesterolemia (FH), a condition in which multiple variants of several different genes lead to markedly high cholesterol. This greatly increases the risk of heart attack, stroke, and other health problems. FH affects about one in 300 adults, which means it isn’t rare. Among adults who have the most common genetic variants that cause it, heart attack or sudden cardiac death may occur in middle age. Children who have a double dose of a gene variant linked to this condition may die of cardiovascular disease before age 20. Earlier treatments intended to reduce the risk of complications, such as cholesterol-lowering drugs, are available if a child or adult is known to have a mutation linked to FH.
These tests can often allow doctors to see what’s going on that they may not be observing in a physical examination — things that don’t manifest in the body. But such hereditary and congenital diseases are rare. DNA is not destiny: People are complex, and there are many things that affect someone’s health and ability to be healthy — from environmental to genetic. Your DNA is saying who you are—– not what you can and can’t be. And that’s an important message. For example, Andrew Steel, a 400-metre runner and former Olympian, discovered that he didn’t have what is called ‘the sprint gene’, one of a pair of genes that almost all other Olympic sprinters have. Had he been told at an early age ‘you don’t have this gene, so you’ll never amount to anything in sport’, he may not have gone on to become an Olympic medal-winning runner. The example also demonstrates the importance of reputable advice on how to interpret the results of DNA health tests.
Our studies identified the relationship between Coronavirus and Genetics. We performed genetic analysis with more than 300 coronavirus patients in Brazil. We divided into 3 groups. A group of patients in the ICU in serious condition. A group with patients in the hospital but in a moderate state and a group with patients at home, with mild manifestation of the disease. We have a tool capable of predicting which individuals are at greater or lesser risk for the pandemic, and regarding vaccine risks. Discover more details at Roberto Grobman CSO.